Global equity markets took a dive over the Chinese New Year holidays after news of an outbreak of the coronavirus left markets in limbo. The virus, first detected in the Wuhan City of China, led to a complete lock-down of the city as China’s government rushed to contain the spread of the virus. The move disrupted the world’s largest human migration, as the Chinese New Year typically sees 3 billion trips being made as families reunite to celebrate the festive holidays. After being closed for the festive holidays and an extended break from the coronavirus, the China equity market is set to open for trading this week.


In the news

  • The death toll from the coronavirus in China exceeded 300, with infections being seen spreading amidst more countries putting in place travel bans as fears intensified.
  • The World Health Organization (WHO) declared the coronavirus a global health emergency – but specified that it would not be interfering with global travels, and trade.
  • US stocks suffered declines on concerns that the outbreak would dampen economic growth. This occurred amidst a busy week of corporate earnings where companies were releasing better than expected corporate profits.
  • A standout winner was Apple Inc, which saw its stock price hit a record high amidst the uncertainty after announcing strong earning results. It’s quarterly revenue rose 9% from the previous year to USD 91.8 billion.
  • However, fears of the coronavirus overshadowed earnings results, putting price pressures on stocks despite their earning results. Other strong earners included
    • Amazon, Inc - whose revenue grew by 21% YoY to US 87.4 billion), and
    • Facebook, Inc – whose growth beat estimates but was slower than its previous years.
  • 0831EA (TradePlus NYSE FANG+ Daily (-1x) Leveraged Tracker) provided a hedge from the market tumble, gaining 0.8% last week amidst the market volatility, while the NYSE FANG+ Index rose 0.5% over the same period.
  • Brexit finally took place on the 31st of January, when the UK left the EU more than 3 years after voting on the referendum.  This left the UK prepping itself for more negotiations for its future trade ties with the EU. 
  • The uncertainties that have hovered over markets have driven gold prices higher, pushing the 0828EA (TradePlus Shariah Gold Tracker) 2.2% higher last week, alongside LBMA Gold price which rose 2.0% over the same period. 


In other economic news

  • US Feds kept its interest rates unchanged, as it continued to work towards achieving its 2% inflation target.
    • GDP for 4Q2019 was recorded at a 2.1%, bringing the US’ full year growth to 2.3%, down from the 2.9% seen in 2018.
    • Consumer spending slowed in 4Q to 1.8%, a relatively large slowdown from the 4.6% in 2Q, and 3.2% in 3Q.
  • The EU saw unexpectedly weaker growth, with the bloc recording a mere 0.1% growth in 4Q.  Weakness was attributed to widespread strikes that were seen taking place in France, political confusion in Italy, as well as the overall weakness in trades on the global front.  The broader European Index slid 1.9% lower in MYR terms last week.
  • Over in China, economic data was mixed.
    • The manufacturing sector posted a PMI reading of 50.0, slowing marginally from the 50.2 reading in December – signalling a stagnation.
    • Non-manufacturing index was however seen to be improving with a reading of 54.1, beating the estimated 53.0, and the previous month’s reading of 53.5.


What to look out for ahead?

  • The China equity market opens this week after taking a break in conjunction with the Chinese New Year and an extended close following the virus outbreak. Market is expected to open softer this week following the declines seen across global financial markets. 
  • China has vowed to provide financial support for its financial system in excess of CNY 170 billion to cushion the impact of the virus outbreak on the economy.  
  • Would this government support provide an opportunity for investors to take advantage of the sell-off and move back into the market through the 0832EA (TradePlus HSCEI Daily (2x) Leveraged Tracker), or is it time to hedge exposure through the 0833EA (TradePlus HSCEI Daily (-1x) Inverse Tracker)?
  • US corporate earnings will continue on this week – and we will be watching out for earnings from Google’s parent Alphabet to see if the NYSE FANG+ Index will continue to climb higher in a sea of red performers, which it had done last week.
  • The US is also expected to release its ISM manufacturing PMI numbers, as well as its non-farm payroll data this week.
  • But all these will probably be overshadowed by the coronavirus, as markets continue to watch the latest development and its potential impact on global financial markets.
  • Are we expecting more pressures for the equity market and time to hedge your portfolios, or is it time to increase your market exposure after the sell-off? 


A look at the performance of the TradePlus ETFs, and major global indices

Source: AHAM Capital as at 31 Jan 2020. Prices and returns are quoted in MYR terms, and reflects the closing NAV of the ETF.


Source: Bloomberg as at 31 Jan 2020. Returns are quoted in MYR terms.


Get in touch
+(60) 12 606 8685


Disclaimer: This article has been prepared by AHAM Asset Management Berhad (“AHAM Capital”) specific for its use, a specific target audience, and for discussion purposes only. All information contained within this presentation belongs to AHAM Capital and may not be copied, distributed or otherwise disseminated in whole or in part without written consent of AHAM Capital. The information contained in this presentation may include, but is not limited to opinions, analysis, forecasts, projections and expectations (collectively referred to as “Opinions”). Such information has been obtained from various sources including those in the public domain, are merely expressions of belief. Although this presentation has been prepared on the basis of information and/or Opinions that are believed to be correct at the time the presentation was prepared, AHAM Capital makes no expressed or implied warranty as to the accuracy and completeness of any such information and/or Opinions. As with any forms of financial products, the financial product mentioned herein (if any) carries with it various risks. Although attempts have been made to disclose all possible risks involved, the financial product may still be subject to inherent risk that may arise beyond our reasonable contemplation. The financial product may be wholly unsuited for you, if you are adverse to the risk arising out of and/or in connection with the financial product. AHAM Capital is not acting as an advisor or agent to any person to whom this presentation is directed. Such persons must make their own independent assessments of the contents of this presentation, should not treat such content as advice relating to legal, accounting, taxation or investment matters and should consult their own advisers. AHAM Capital and its affiliates may act as a principal and agent in any transaction contemplated by this presentation, or any other transaction connected with any such transaction, and may as a result earn brokerage, commission or other income. Nothing in this presentation is intended to be, or should be construed as an offer to buy or sell, or invitation to subscribe for, any securities. Neither AHAM Capital nor any of its directors, employees or representatives are to have any liability (including liability to any person by reason of negligence or negligent misstatement) from any statement, opinion, information or matter (expressed or implied) arising out of, contained in or derived from or any omission from this presentation, except liability under statute that cannot be excluded.

Warning Statement: A Prospectus is available for the TradePlus Shariah Gold Tracker and TradePlus S&P New China Tracker, while a Master Prospectus is available for the TradePlus NYSE® FANG+TM Daily (2x) Leveraged Tracker, TradePlus NYSE® FANG+TM Daily (-1x) Inverse Tracker, TradePlus HSCEI Daily (2x) Leveraged Tracker and TradePlus HSCEI Daily (-1x) Inverse Tracker (collectively known as the “TradePlus L&I ETFs”), and investors have the right to request a copy of it. Investors are advised to read and understand the contents of the Prospectus dated 28 November 2017 and Supplementary Prospectus dated 2 July 2019 (for TradePlus Shariah Gold Tracker), and Prospectus dated 15 January 2019 and Supplementary Prospectus dated 2 July 2019 (for TradePlus S&P New China Tracker), as well as the Master Prospectus dated 26 November 2019 (for the TradePlus L&I ETFs) before investing. The Prospectus / Supplementary Prospectus / Master Prospectus have been registered with the Securities Commission Malaysia, who takes no responsibility for its contents. An electronic copy of the Prospectus / Supplementary Prospectus / Master Prospectus can be obtained at Affin Hwang Asset Management Berhad’s website As with any forms of financial products, the financial products mentioned herein carries with them various risks. Investors are advised to consider the general and specific risks involved as stipulated in its Prospectus / Supplementary Prospectus / Master Prospectus before investing. There are also fees and charges involved when investing in these funds, and investors are advised to consider the fees and charges carefully before investing. The price of units and distribution payable, if any, may go down as well as up and past performance of the funds should not be taken as indicative of their future performance. 

Licensing Disclosure Statement & Conditions: The "S&P New China Ex A-Shares Index" is a product of S&P Dow Jones Indices LLC, a division of S&P Global, or its affiliates (“SPDJI”) and has been licensed for use by Affin Hwang Asset Management Bhd. Standard & Poor’s® and S&P® are registered trademarks of Standard & Poor’s Financial Services LLC, a division of S&P Global (“S&P”); Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC (“Dow Jones”) and these trademarks have been licensed for use by SPDJI and sublicensed for certain purposes by Affin Hwang Asset Management Bhd. TradePlus S&P New China Tracker is not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P, their respective affiliates and none of such parties make any representation regarding the advisability of investing in such product(s) nor do they have any liability for any errors, omissions, or interruptions of the S&P New China Ex A-Shares Index.

Licensing Disclosure Statement & Conditions: Source ICE Data Indices, LLC (“ICE Data”), is used with permission. “NYSE® FANG+™” is a service/trade mark of ICE Data Indices, LLC or its affiliates and has been licensed, along with the NYSE® FANG+™ Daily 2X Leveraged Index and NYSE® FANG+™ Daily 1x Inverse Index (“Indices”) for use by Affin Hwang Asset Management Berhad in connection with the TradePlus NYSE® FANG+™ Daily (2x) Leveraged Tracker and the TradePlus NYSE® FANG+™ Daily (-1x) Inverse Tracker (the “Product”). Neither Affin Hwang Asset Management Berhad nor the Product, as applicable, is sponsored, endorsed, sold or promoted by ICE Data Indices, LLC, its affiliates or its Third Party Suppliers (“ICE Data and its Suppliers”). ICE Data and its Suppliers make no representations or warranties regarding the advisability of investing in securities generally, in the Product particularly, or the ability of the Index to track general stock market performance. ICE Data’s only relationship to Affin Hwang Asset Management Berhad (“Licensee”) is the licensing of certain trademarks and trade names and the Index or components thereof. The Index is determined, composed and calculated by ICE Data without regard to the Licensee or the Product or its holders. ICE Data has no obligation to take the needs of the Licensee or the holder of the Product into consideration in determining, composing or calculating the Index. ICE Data is not responsible for and has not participated in the determination of the timing of, prices of, or quantities of the Product to be issued or in the determination or calculation of the equation by which the Product is to be priced, sold, purchased, or redeemed. Except for certain custom index calculation services, all information provided by ICE Data is general in nature and not tailored to the needs of Licensee or any other person, entity or group of persons. ICE Data has no obligation or liability in connection with the administration, marketing, or trading of the Product. ICE Data is not an investment advisor. Inclusion of a security within an index is not a recommendation by ICE Data to buy, sell, or hold such security, nor is it considered to be investment advice.